Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c2741412abe407fb173b5d21cca3187f |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-341 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0644 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L26-009 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L26-0047 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L26-0057 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08L89-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4833 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-16 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L24-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-19 |
filingDate |
2019-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ccefde3c030656c0697f5c542bb9cbe6 |
publicationDate |
2020-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2020115503-A1 |
titleOfInvention |
Wound treatment gel obtainable by combining platelet rich plasma with autologously derived thrombin |
abstract |
The present invention provides a method of making a wound treatment composition, wherein the method comprises; i) fractionating a whole blood sample into multiple samples including a platelet rich plasma (PRP) sample,a platelet poor plasma (PPP) sample and a erythrocyte sample, wherein the PRP sample has a haematocrit level of 1-10%, ii) processing a portion of the PPP and/or PRP sample to facilitate cleavage of autologous pro-thrombin present in the PPP and/or PRP to produce autologous thrombin, and iii) combining the PRP sample with a portion of the PPP sample and a portion of the thrombin produced in step (ii) to produce the wound treatment composition; wherein step ii) is performed at less than 15 °C. In preferred embodiments the PRP has a haematocrit level of 2 or 8%. Wound treatment compositions produced by the methods are also provided as are compositions for use in treating chronic and acute wounds. |
priorityDate |
2018-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |